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Abstract
Background
Smoking is known to have a negative impact on both morbidity and mortality in people
living with HIV (PLHIV). However, there is inconsistent information about the role of smoking
on markers of HIV disease progression (CD4 count and HIV viral load). This study examined the
effects of cigarette smoking on markers of HIV disease progression among PLHIV at Nebraska
Medicine.
Methods
A retrospective cohort study was conducted utilizing electronic health information of 604
PLHIV who attended treatment at Nebraska Medicine between 2012 and 2020. Multiple linear
regression was used to model the effects of smoking on the mean change in CD4 count between
the first two visits while adjusting for other covariates. Also, multiple logistic regression was used
to model the effects of smoking on viral load suppression status (having <200 copies/ml at both
visits or at the second visit versus having >=200 copies/ml at both visits or at the second
visit).Other covariates were age at the first visit, sex, and race.
Results
The prevalence of current cigarette smoking was 40.7%. In the analysis of patients
regardless of the Antiretroviral Therapy status(ART), older patients had less gain in CD4 count
compared to younger patients (-1.16, 95%CI=-2.24,-0.067, p=0.03). However, older patients were
more likely to be virally suppressed compared to younger patients (OR=1.02, 95% CI=1.003,
1.044, p=0.03). In the analysis of patients who were on ART, never-smokers had better gain in
CD4 count compared to current smokers (OR=162.688, 95%CI=1.47, 243.88, p=0.0001). Also,
females had less gain in CD4 count compared to males (-97.39, 95%=-188.29,-6.48, p=0.036).
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Conclusion
The findings of lesser CD4 count recovery among current smokers compared to neversmokers indicate the need to implement Public health programs targeting smoking prevention and
cessation among PLHIV.

SPECIFIC AIMS
The objective of this study was to examine the association of cigarette smoking with the HIV
disease progression.
This study had two specific aims as listed below.
Specific aim 1: The study examined the association between cigarettes smoking and the mean
change in CD4 counts between the first and the second hospital visit in people living with HIV.
Specific aim 2: The study examined the association between cigarettes smoking and viral load
status (suppressed v/s not suppressed) during the first and second hospital visit in people living
with HIV.
The study hypotheses were: 1) cigarette smoking is associated with a lower CD4 count.
2) Cigarette smoking is associated with a higher HIV viral load.
This study is of significance because the results help to characterize the distribution of cigarette
smoking among HIV patients who are attending treatment at Nebraska Medicine, and also help in
explaining the effects of cigarettes smoking on disease progression in people living with HIV.
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Background
There is great progress in the prevention and control of Human Immunodeficiency Virus
(HIV) infections. HIV infection affects the health of a person by gradually destroying white blood
cells with CD4 receptors with subsequent development of Acquired Immunodeficiency Syndrome
(AIDS) [4]. Since the onset of the HIV epidemic in the early 1980s, the disease has claimed the
life of more than 32 million people [7]. The first breakthrough in the fight against the HIV/ AIDS
epidemic came in 1987 when azidothymidine (AZT) was approved in the treatment of AIDS [5].
However, a major significant point was reached in 1996 when a combination of triple therapy was
shown to be effective in attaining viral suppression and preventing resistance of HIV [5]. Since
then, the introduction of new superior medications and the implementation of evidence-based
management and prevention programs has led to a decrease in both the number of new HIV
infections and the number of AIDS-related deaths. Currently, people living with HIV have a longer
life span compared to previously.
Worldwide, there are approximately 37.9 million people who were living with HIV in 2018,
and approximately 770 thousand people died from HIV/AIDS in the same year. Furthermore, the
number of new HIV infections was 1.8 million in the same year [7]. The greater burden of the HIV
disease is in sub-Saharan Africa, where 70% of the HIV patients are residing [6].
In the USA, the estimated number of people living with HIV was 1.1 million in 2018. The
number of new HIV infections was 37,832 in the same year [1]. There is a decrease in the number
of new HIV infections in the USA: the number decreased by 7.9% from 41,800 to 38,800 in five
years (2011-2015) [19]. However, the distribution of HIV infections is not -uniform in the USA;
it varies according to geographical location, gender, transmission category, and race. The South of
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the USA leads with a number of new HIV infections, and the Midwest has the least number of new
infections [8,19].
In 2018, the number of new infections increased in people aged 25-30 years. However, the
number of new infections decreased in all other age groups, except people aged above 55 years
where it remained stable [19]. Furthermore, the number of new HIV infections decreased in
females while it remained stable in males. The number of new HIV infections remained stable in
homosexuals, a group with the largest share of HIV infections since the onset of the epidemic
[19,32]. In Nebraska, the average number of new annual infections was 95 in a period of ten years
from 2006 to 2015. Moreover, 82% of new HIV infections were concentrated in Sarpy, Douglas,
and Lancaster counties [9].
Despite being successful in reducing morbidity and mortality in people living with HIV,
Antiretroviral Therapy (ARTs) has been established as a major way to decrease the number of HIV
infections [20]. The medications(ARVs) suppress viral replication and hence decreased the risk of
transmitting HIV to other people [20]. The majority (92%) of new HIV infections occur in people
who are undiagnosed and from people who are not on treatment. However, there is 8% of new
infections that occur to those who are on treatment and mostly from those who have not achieved
viral suppression [18].
Several factors have been associated with HIV disease progressions such as age at
diagnosis, sex of the patient, socioeconomic status, ART adherence, and other comorbidities.
However, there are inconsistent pieces of evidence regarding the association of cigarette smoking
with markers of HIV disease progression (CD4 count and HIV viral load). Some studies have
reported that cigarette smoking is associated with lower CD4 count recovery and less chance of
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viral load suppression. In contrast, other studies have found no association between smoking and
markers of HIV disease progression(CD4 count and viral load ) [21, 24, 28, 29, 30].
This study was conducted to explore the association between cigarette smoking and markers
of HIV infection disease progression among a cohort of patients attending treatment at Nebraska
Medicine. The result of this study is important to explain the effects of cigarette smoking on HIV
infection disease progression and in characterizing the distribution and magnitude of cigarette
smoking among HIV positive patients in Nebraska. The results of this study will add knowledge
in areas relating to HIV treatment and prevention.
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METHODS

Study population and settings

This study utilized the electronic health records of patients who attended treatment at the
University of Nebraska Medical Center/Nebraska Medicine (UNMC/NM) between 2012 and
2019. The majority of people (71%) who are attending treatment at UNMC/NM are residing in
Douglas and Sarpy Counties[10]. Patient information is routinely collected and stored in a database
that was established and is maintained by the Nebraska Public Health Laboratory. The database
includes information such as hospital visits, demographic characteristics, clinical characteristics,
and other behavioral information. The data are de-identified using a special ID to preserve the
patient’s confidentiality.

Inclusion and exclusion criteria
This study included patients who were on treatment between January 2012 and February
2020 at Nebraska Medicine, and who had complete information on smoking status, laboratory
results( CD4 count, and HIV viral load), and other relevant demographic characteristics (age, race,
and sex). Patients who lacked smoking status information at baseline were excluded from the
study.
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Exposures
The main exposure of interest was cigarette smoking status. Smoking status was
categorized as current smokers, former smokers, and never-smokers. Other exposures were age at
the first visit, sex (male v/s female), and Race (Whites, African American, and others). Also,
information on the use of Antiretroviral Therapy was collected.

Outcomes

The primary outcome was the change in CD4 count between the first and the second visit.
Approximately 67% of the patients had a second visit between 3 to 6 months. The secondary
outcome was Viral load status (suppressed v/s not suppressed) during the follow-up period.
Patients who maintained a viral load of <200 copies at both visits, together with patients who
improved during the follow-up period( changing from a viral load of >=200 copies to a viral load
of <200 copies ) were categorized as a suppressed. In contrast, patients who maintained a viral
load of >=200 at both visits, together with patients who deteriorates(changing from a viral load of
<200 copies to a viral load of >=200) were assigned as not suppressed. Approximately 93% of the
patient had a second visit between 3 and 6 months.
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Statistical analysis
Frequencies and percentages were used to describe the distribution of the categorical
variables (sex, race, categorized age-groups, categorized CD4 counts, and categorized HIV viral
load). Chi-square tests were used to test for differences in distribution between different
categorical variables indexed by smoking status. Non-parametric Kruskal-Wallis tests were used
to test for the differences in median ages among the different categories of smoking. The same
tests were used to test for differences in median CD4 count and mean Viral load among different
categories of smoking. Multiple linear regression was used to model the effects of cigarette
smoking on the mean change in CD4 counts between the first visit and the second visit. Age, Sex,
Race, and CD4 count at the first visit were used as other predictors. The non-normal distribution
of the viral load necessitates categorizing viral load into a binary variable. And then, multiple
logistic regression was used to model the effects of cigarette smoking on the viral load status
(suppressed versus not suppressed) during the follow-period. Age at the first visit, sex, and race
were used as other predictors. Because viral load of zero is illogical, then we assigned a value of
half the lowest viral load(10 copies/ml) to the not detectable viral load results. The analysis was
conducted using the statistical software SAS v. 9.4 (SAS Inst, Cary, NC).
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RESULTS SECTION

Characteristics of the study participants
A total of 604 PLHIV with complete information on smoking, laboratory, and demographic
characteristics were included in this study at the baseline. There were 246 (40.7%) current
smokers, 248 (41.1%) never -smokers, and 110 (18.2%) former smokers. Four hundred and ninetysix (82.12%) of the patients were males, while the remaining 108 (17.88%) were females. Two
hundred and seventy-nine (46.19%) of the patients aged between 30 and 50 years, while 171
(28.31%) patients aged below 30 years, and the remaining 154 (25.50%) patients aged above 50
years. Three hundred and eighty-four (65.58%) patients were of the white race, while 163 (26.99%)
patients were of African American race, and the remaining 57 (9.44%) patients were of other races.

The median age of the patients at first visit was 39.8 years (Range: 2.4-78). The median
differences in age at first visit among smoking categories were statistically significant (p=0.0031).
Specifically, former smokers were older (Median=45 years, Range: 13.8-78.4) compared to
smokers (Median=39, Range:21-70.8), and never-smokers (Median=37.6, Range: 2.4-76.7).
Furthermore, there was a statistically significant association between the age category and the
Smoking category (p=0.03). Specifically, there were more current smokers in the age-group 30<50 years compared to other age categories.

The median CD4 count at the first visit was 446 cells/μl (Range:2-1955), while the median
CD4 count during the second visit was 482 cells/μl (Range: 4-2083). At the first visit, there were
264 patients (44.00%) with a CD4 count of >500 cells/mm3, 215 patients (35.83%) with a CD4
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count of 200-<500 cells/mm3, and 121 (20.17%) patients with a CD4 count of <200 cells/mm3.
Four patients had missing information on CD4 count at first visit. At the second visit, there were
216 patients (47.26%) with a CD4 count of >500 cells/mm3, 166 patients (36.32%) with a CD4
count of 200-<500 cells/mm3, and 75 patients (16.41%) with a CD4 count of <200 cells/mm3. One
hundred and forty-seven patients had missing information on CD4 count at the second visit.

The median HIV viral load at the first visit was 1189 copies (Range:10-10,000,000), while
the median HIV viral load during the second visit was 19.95 copies (Range: 10-10,000,000). Three
hundred and forty-two (55.52%) patients were not virally suppressed during the first visit. In
contrast, 428 (85.43%) achieved viral suppression during the second visit. One hundred and three
patients had missing information on viral load at the second visit.

Effects of cigarettes smoking on the mean change in CD4 counts and viral load status
Two analyses were conducted in this study. The first analysis included patients regardless
of their ART status, and the second analysis(sub-analysis) included patients who were on ART.
The results of the first analysis are presented in table 2 and table 3, and the results of the second
analysis are presented in table 4 and table 5.

In the unadjusted analysis of 457 patients with complete CD4 count results at both visits,
the exposures (sex, race, and smoking status) were not associated with mean change in CD4 count
(p-value>0.05). However, age at first visit was marginally associated with the mean change in CD4
count (p=0.054). In the adjusted analysis of 457 patients, the age of the patient at the first visit was
significantly associated with the mean change in CD4 counts (-1.16, 95%CI=-2.24,-0.067,
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p=0.03). Specifically, the mean difference in CD4 count decreased by 1.16 in a group of patients
who were one year older compared to a group of younger patients. The mean difference in CD4
count was not associated with smoking status, gender, and race in the adjusted analysis.

The adjusted analysis of 501 patients showed that age at first visit was significantly
associated with viral load suppression status (OR=1.022, 95%CI 1.002, 1.042, p=0.035). Similarly,
in the adjusted analysis, the age of the patient at the first visit was significantly associated with
viral load suppression status (OR=1.02, 95% CI=1.003, 1.044, p=0.03). Specifically, the odds of
having a suppressed viral load status was 2% higher for a group of patients who were one year
older compared to a younger group. The analyses of the association of other variables( smoking,
gender, and race) and viral load status were not statistically significant (p>0.05).

Effects of cigarettes smoking on the mean change in CD4 counts and viral load status for
patients who were on ART

In the unadjusted analysis of the 57 patients who were on ART, the mean change in CD4
count increased by 151.57 cells/mm3 in never smokers compared to current smokers(151.57,
95%CI=69.05, 234.079). Similarly, in the adjusted analysis, the mean change in CD4 count
increased by 162.68 cells/mm3 in never smokers compared to current smokers(OR=162.688,
95%CI=1.47, 243.88, p=0.0001).

The unadjusted analysis of the relationship between gender and mean change in CD4 count
was not significant(p=0.2). However, the adjusted analysis of the relationship between gender and
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mean change in CD4 count was significant (p=0.036).Specifically, the mean change in CD4 count
decreased by 97.39 in females compared to males. Other variables (age at the first visit, and race)
were not statistically significantly associated with mean CD4 count change. The relationship
between all predictors(smoking, age at the first visit, race, and sex) and viral load status was not
statistically significant (p>0.05).

DISCUSSION
The prevalence of current cigarette smoking among PLHIV in this study was 40.7%.
Several other studies have found a similarly high prevalence of smoking among PLHIV. These
studies have documented the prevalence of current cigarette smoking to be above 40% among
PLHIV compared to 19% of the general US population [22, 23]. The median age of former smokers
was higher compared to the median ages of current smokers and never-smokers. Furthermore,
there are more current smokers aged 30-50 years compared to current smokers aged below 30
years and aged above 50 years. For patients of the White race and African American race, there
were more current smokers compared to other smoking categories. In contrast, for patients of other
races, there were more never-smokers compared to other smoking categories. These findings of
the distribution of age category and race according to smoking status highlights the importance of
scaling up efforts of cigarettes smoking prevention/cessation programs in HIV patients aged 3050 years, and HIV patients of White race and African American race.
Current smokers seemed to have a higher median CD4 count at first visit compared to both
never-smokers and former smokers. However, this relationship was not statistically significant(pvalue=0.101). Other studies have found that HIV positive smokers tend to have higher CD4 count
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at baseline compared to HIV positive never-smokers [24]. Furthermore, other studies have found
that even in HIV negative individuals, smokers have higher CD4 count compared to non-smokers
[25]. There is evidence that smoking promotes immune activation in both HIV positive and HIV
negative patients [25]. However, the advantage of having higher CD4 count in smokers is offset
by the diminishing normal functioning of those CD4 cells[25]. The analysis of patients who were
on ARTs found that compared to smokers, never smokers have better improvement in CD4 count.
Other studies have found similar results that never-smokers have better CD4 count recovery
compared to smokers when on treatment [21].
In this study, for patients who were on ART, females gained less CD4 cells during the
follow-up period compared to males. There is contrasting information about the relationship
between sex and CD4 count. One study conducted in South Africa showed that for patients who
are on treatment, females have better improvement in CD4 count compared to males [32]. Another
study conducted in Uganda showed that there was no difference in CD4 count recovery between
males and females [33]. However, one study conducted in Tanzania showed that males have a
better CD4 recovery compared to females [34].
Smoking was not associated with viral load status during the follow-up period. Similarly,
other studies have found that there is no relationship between smoking and viral load suppression
[31]. However, several other studies have found that smokers are less likely to achieve viral
suppression compared non-smokers [24,28,29]. Two studies investigated the effect of both
smoking frequency and smoking quantity on HIV viral load suppression, one study found that
daily smoking is associated with less likely chance of viral suppression, while the second study
found that quantity of cigarettes smoking rather than frequency is associated with detectable viral
load [29, 30].
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This study found that age at first visit, which was a proxy for age at baseline, was associated
with viral load suppression status. Older HIV patients were more likely to have a viral suppression
status compared to younger patients. Two studies have reported similar relationship between age
and HIV viral load suppression: old age at diagnosis is associated with better viral load status
[26,27].
There are several limitations to this study which might distort the true relationship between
the exposures(smoking, age at first visit, sex, and race) and outcome(mean change in CD4 count,
and viral load status). First, the analysis of the larger sample size was done regardless of whether
the patient was on medication or not. ARTs have a greater influence on both outcomes, CD4 count,
and viral load. The second limitation is that, because of the secondary nature of the data, this study
could not get the quantitative measure of the exposure (smoking). The quantitative measure of
smoking would be much more informative in assessing the dose-effect response. Also, lack of
information on adherence to ART, socio-economic status, and alcohol might distort the
relationship of the effects of cigarette smoking on markers of HIV disease progression.
Conclusively, the higher prevalence of cigarette smoking in PLHIV together with a poor
CD4 count recovery in smokers compared to never smokers indicate the need to put in place Public
Health measures in targeting smoking prevention and cessation in PLHIV.
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Appendices
Table 1: Demographic and clinical characteristics of the sample patients according to smoking categories
Characteristic
All Patients (N=604)
Smokers(N=246)
Former
Never
smokers(N=110)
smokers(N=248)
39 (21-70.8)
45 (13.8-78.4)
37.6 (2.4-76.7)
Median Age at First Visit 39.8 (2.4-78)
Age Category
<30
30-<50
>=50
Gender
Male
Female
Race
Black
White
Other
CD4 count (cells/μl)
First visit
Median CD4 counts
CD4 counts category
Stage 3 ( <200)
Stage 2 (200-<500)
Stage 1 (>500 )
Second visit
Median CD4 count
CD4 counts category
Stage 3 ( <200)
Stage 2 (200-<500)
Stage 1 (>500 )
HIV Viral Load(VL)
First visit
Median VL
HIV viral loads category
Suppressed <200
Detectable >=200
high Viral load > 100,000
Second visit
Median VL
HIV viral loads category
Suppressed <200
Detectable >=200

P-value
0.0031*

171 (28.31%)
279 (46.19%)
154 (25.50%)

68 (39.77%)
126 (54.16%)
52 (33.77%)

24( 14.04%)
48 (17.20%)
38(24.68%)

79 (46.20%)
105 (37.63)
64 (41.56%)

0.03*

108
496

41 (37.96%)
205 (41.33%)

18 (16.67%)
92(18.55%)

49 (45.37%)
199(40.12%)

0.6021

163 (26.99%)
384 (63.58%)
57 (9.44%)

72 (44.17%)
159 (41.41%)
15 (26.32%)

26 (15.95%)
79 (20.57%)
5 (8.77%)

65 (39.88%)
146 (38.02%)
37 (64.91%)

0.0022*

446 (2-1955)

489 (2-1955)

419 ( 8-1655)

431 (8-1676)

0.1012

121 (20.17%)
215 (35.83%)
264 (44%)

42 (34.71%)
86 (39.63%)
117 (44.15%)

28 (23.14%)
34 (15.67%)
48 (18.11%)

51 (42.15%)
97 (44.70%)
100 (37.74%)

0.099

482 (4-2083)

557.52

537.54

515.47

0.5822

75 (16.41%)
166 (36.32%)
216 (47.26%)

29 (38.67%)
63 (37.95%)
97 (44.91%)

14 (18.67%)
35 (21.08%)
33 (15.28%)

32 (42.67%)
68 (40.96%)
86 (39.81%)

0.1665

1189 (10-10,000,000)

2041 (10-10,000,000)

245 (102511886)

3165 (10-10,000,000)

0.5714

266 (44.04%)
228(37.75%)
110(18.21%)

105 (39.47%)
101 (44.30%)
37 (33.64%)

55 (20.68%)
35 (15.35%)
23 (20.91%)

106 (39.85%)
92 (40.35%)
50 (45.45%)

0.7572

19.95 (0-10,000,000)

19.95 (0-389045)

19.95 (0-794328)

19.95 (0-10,000,000)

0.7464

428(85.43%)
73 (14.57%)

173 (40.42%)
31 (42.47%)

72 (16.82%)
15 (20.55%)

183 (42.76%)
27 (36.9%)

0.5892
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Table 2
Mean Difference in CD4 count between the first two visits (N=457)
Unadjusted analysis
Adjusted analysis
Mean Difference
P
Mean Difference
95%CI
95%CI
-1.08(-2.17,0.02)
0.054**
-1.16(-2.24, -0.067)
Age at First
visit
Gender
Female
Male

-0.44(-37.76, 36.88)
Ref

0.98
-

P
0.03*

4.3708(32.87,41.61)
Ref

0.82
-

Race
Black
other
white
Smoking
Never
Former
Current

18.44(-14.07,50.95)
16.21(-37.24, 69.65)
Ref

0.27
0.26
-

12.66(-19.54,44.86)
8.74(-44.32, 61.81)
Ref

0.44
0.75
-

28.96(-2.78,60.70)
18.15(22.55, 58.85)
Ref

0.07
0.38
-

22.78(-8.67,54.23)
17.71(-22.18,57.59)
Ref

0.16
0.38
-

*Results are statistically significant at p<0.05
**Marginally significant
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Table 3
Factors associated with viral load suppression during the follow-up period
(N=501)
Unadjusted analysis
Adjusted analysis
OR
95%CI
P
OR
P
95%CI
1.022 (1.002, 1.042)
0.035* 1.02(1.003, 1.044)
0.03*
Age at First
visit
Gender
Female
Male

0.88(0.47, 1.62)
Ref

0.67 0.801(0.43, 1.511)
Ref

Race
Black
other
white

0.83 (0.47,1.47)
0.71(0.32,1.57)
Ref

0.53 0.91(0.510, 1.61)
0.4 0.69(0.31,1.57)
Ref

Smoking
Never
Former
Current

1.21(0.70, 2.12)
0.86 (0.44,1.69)
Ref

0.32 1.32(0.74, 2.34)
0.43 0.80(0.41,1.58)
Ref

*Results are statistically significant at p<0.05

0.5
-

0.74
0.38
-

0.34
0.52
-
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Table 4

Mean Differences in CD4 count between the first two visits (N=57)
Unadjusted mean difference
Adjusted mean difference
Mean Difference (95%CI) P
Mean Difference
P
(95%CI)
0.93(-2.60,4.46)
0.6
0.27(-2.82,3.36)
0.86
Age at
First
visit
Gender
Female
Male

-61.45(-156.25, 33.35)
Ref

0.2
-

-97.39(-188.29,-6.48)
Ref

0.036
-

Race
other
white

21.75(-65.07,108.58)
Ref

0.62
-

18.66(-66.35,103.67)
Ref

0.67
-

Smoking
Never
Former
Current

151.57(69.05,234.0792)
54.95(-44.80, 154.70)
Ref

0.0003*
0.28
-

162.68(81.47, 243.88)
29.02(-75.73, 133.76)
Ref

0.0001*
0.59
-

*Results are statistically significant at p<0.05
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Table 5
Factors associated with viral load suppression during the follow-up period
(N=57)
Unadjusted OR
Adjusted OR
OR (95%CI)
P
OR (95%CI)
P
1.05 (0.996,1.095)
0.07 1.035 (0.99,1.09)
0.17
Age at First
visit
Gender
Female
Male

0.70 (0.19,2.51)
Ref

0.58
-

0.66(0.15, 2.99)
Ref

0.59
-

0.612 (0.19,1.99)
Ref

0.41
-

1.08 (0.26, 4.53)
Ref

0.92
-

0.88(0.23,3.44)
0.25(0.05,1.16)
Ref

0.86
0.08
-

0.98(0.223, 4.28)
0.27(0.05,1.52)
Ref

0.98
0.14
-

Race
other
white
Smoking
Never
Former
Current

